{"id":"epidoxorubicin","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Acute infectious disease","Breastfeeding (mother)","Cardiomyopathy","Chronic heart failure","Conduction disorder of the heart","Disease of liver","Hepatic failure","Kidney disease","Life-Threatening Cardiac Arrhythmias","Myocardial infarction","Neutropenic disorder","Pregnancy, function","Severe Bone Marrow Depression","Stomatitis","Thrombocytopenic disorder"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Tyrosine-protein kinase Fyn, 5-hydroxytryptamine receptor 4, Genome polyprotein"},"_scrapedAt":"2026-03-28T01:51:27.845Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Carcinoma of breast","diseaseId":"carcinoma-of-breast","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT00066443","phase":"PHASE1, PHASE2","title":"Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2003-11-03","conditions":"Breast Cancer","enrollment":93},{"nctId":"NCT07491822","phase":"NA","title":"A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-03-25","conditions":"TNBC","enrollment":43},{"nctId":"NCT06831955","phase":"PHASE2","title":"LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2026-02-01","conditions":"Triple Negative Breast Cancer (TNBC), Early Setting","enrollment":356},{"nctId":"NCT07480382","phase":"NA","title":"Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC","status":"NOT_YET_RECRUITING","sponsor":"Hong Wu","startDate":"2026-04-01","conditions":"Initially Unresectable Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT04031677","phase":"PHASE3","title":"Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2021-01-20","conditions":"Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma","enrollment":250},{"nctId":"NCT06797635","phase":"PHASE2","title":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Breast Neoplasms, Breast Cancer","enrollment":372},{"nctId":"NCT00911911","phase":"NA","title":"Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2007-02-22","conditions":"Breast Cancer","enrollment":66},{"nctId":"NCT07449949","phase":"","title":"A Single-Arm Study on the Efficacy of Sequential Chemoradiotherapy Followed by Surgery in Adult Nasal and Paranasal Sinus Rhabdomyosarcoma","status":"ENROLLING_BY_INVITATION","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2025-10-30","conditions":"ORR, PFS, OS","enrollment":43},{"nctId":"NCT07449065","phase":"","title":"CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2018-06-01","conditions":"Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization, Microvascular Invasion (MVI)","enrollment":324},{"nctId":"NCT07342283","phase":"PHASE2","title":"QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Affiliated Hospital of Nantong University","startDate":"2026-02-25","conditions":"Triple Negative Breast Cancer (TNBC)","enrollment":30},{"nctId":"NCT07441460","phase":"PHASE3","title":"A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2026-03-07","conditions":"Resectable HER2-positive Breast Cancer","enrollment":1800},{"nctId":"NCT07162051","phase":"PHASE2","title":"A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2023-03-03","conditions":"HR+/HER2- Early Breast Cancer","enrollment":28},{"nctId":"NCT06802757","phase":"PHASE2","title":"Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-05-01","conditions":"Breast Cancer","enrollment":72},{"nctId":"NCT07424287","phase":"PHASE3","title":"A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-03","conditions":"NMIBC","enrollment":236},{"nctId":"NCT06829199","phase":"PHASE2","title":"A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-26","conditions":"Early Triple Negative Breast Cancer","enrollment":""},{"nctId":"NCT05296317","phase":"NA","title":"Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration","status":"COMPLETED","sponsor":"Centre Georges Francois Leclerc","startDate":"2022-09-02","conditions":"Localized Breast Cancer","enrollment":97},{"nctId":"NCT07410559","phase":"PHASE2","title":"Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-07-01","conditions":"Breast Cancer","enrollment":189},{"nctId":"NCT06291064","phase":"PHASE2","title":"Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":"Triple Negative Breast Cancer","enrollment":85},{"nctId":"NCT07410234","phase":"PHASE2","title":"Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02-21","conditions":"Breast Cancer","enrollment":110},{"nctId":"NCT02624973","phase":"PHASE2","title":"PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2016-04-15","conditions":"Breast Cancer","enrollment":200},{"nctId":"NCT06009627","phase":"PHASE2, PHASE3","title":"Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-04-11","conditions":"Breast Cancer","enrollment":119},{"nctId":"NCT07383818","phase":"PHASE2","title":"Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2026-02-01","conditions":"HR Positive/HER2 Low Breast Cancer","enrollment":111},{"nctId":"NCT04067037","phase":"PHASE2","title":"Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2019-08-26","conditions":"Classical Hodgkin Lymphoma","enrollment":60},{"nctId":"NCT07380633","phase":"PHASE2","title":"Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-23","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":90},{"nctId":"NCT07378306","phase":"PHASE2","title":"FMD and Neoadjuvant Chemo-immunotherapy in TNBC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT06144944","phase":"PHASE3","title":"Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-01-17","conditions":"Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma","enrollment":160},{"nctId":"NCT06627712","phase":"PHASE3","title":"SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2024-11-01","conditions":"TNBC - Triple-Negative Breast Cancer","enrollment":318},{"nctId":"NCT07372079","phase":"PHASE2","title":"Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-04-05","conditions":"Breast Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitors","enrollment":40},{"nctId":"NCT07320508","phase":"PHASE2","title":"Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2026-01-20","conditions":"Adenoid Cystic Carcinoma, Sinonasal Carcinoma, Epirubicin","enrollment":100},{"nctId":"NCT03879577","phase":"PHASE2","title":"Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2019-11-25","conditions":"Breast Cancer, Breast Cancer Female, HER2-positive Breast Cancer","enrollment":53},{"nctId":"NCT05909332","phase":"PHASE3","title":"Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-06-20","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":764},{"nctId":"NCT07351487","phase":"PHASE2","title":"Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-09-25","conditions":"TNBC - Triple-Negative Breast Cancer","enrollment":37},{"nctId":"NCT06513364","phase":"PHASE1","title":"Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer","status":"COMPLETED","sponsor":"Beijing Wehand-Bio Pharmaceutical Co., Ltd","startDate":"2024-09-10","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT06682195","phase":"PHASE2","title":"Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-10-09","conditions":"TNBC, Triple Negative Breast Cancer","enrollment":35},{"nctId":"NCT04770272","phase":"PHASE2","title":"Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy","status":"TERMINATED","sponsor":"Palleos Healthcare GmbH","startDate":"2021-03-01","conditions":"Triple-negative Breast Cancer","enrollment":442},{"nctId":"NCT06967103","phase":"PHASE2","title":"QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2025-09-08","conditions":"Breast Cancer, HR+/HER2- Breast Cancer","enrollment":238},{"nctId":"NCT07322848","phase":"PHASE3","title":"DEB-TACE vs cTACE in HCC After TIPS","status":"RECRUITING","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2025-12-01","conditions":"Hepatocellular Carcinoma (HCC), TACE, TIPS","enrollment":206},{"nctId":"NCT04290793","phase":"PHASE2, PHASE3","title":"Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2020-03-01","conditions":"Breast Cancer","enrollment":113},{"nctId":"NCT04872985","phase":"PHASE2","title":"Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-04-20","conditions":"Breast Cancer, Hormone-receptor Positive Breast Cancer","enrollment":140},{"nctId":"NCT07317778","phase":"PHASE2","title":"Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-15","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast Cancer","enrollment":249},{"nctId":"NCT06452394","phase":"PHASE2","title":"NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline","status":"RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2025-07-16","conditions":"Breast Cancer","enrollment":50},{"nctId":"NCT06112379","phase":"PHASE3","title":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-14","conditions":"Breast Cancer","enrollment":1902},{"nctId":"NCT07281664","phase":"NA","title":"Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2026-01-01","conditions":"Hepatocellular Carcinoma, Transarterial Chemoembolization","enrollment":30},{"nctId":"NCT06107673","phase":"PHASE2","title":"Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2023-09-30","conditions":"Breast Cancer","enrollment":144},{"nctId":"NCT06421948","phase":"PHASE1, PHASE2","title":"Linperlisib Combined With Chidamide in Patients With PTCL","status":"RECRUITING","sponsor":"Yanyan Liu","startDate":"2024-05-25","conditions":"Peripheral T-cell Lymphoma","enrollment":134},{"nctId":"NCT02688803","phase":"PHASE4","title":"Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC)","status":"TERMINATED","sponsor":"Ottawa Hospital Research Institute","startDate":"2016-08-30","conditions":"Breast Cancer","enrollment":2},{"nctId":"NCT07256964","phase":"PHASE2","title":"Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2025-11-26","conditions":"TNBC - Triple-Negative Breast Cancer","enrollment":216},{"nctId":"NCT07254858","phase":"PHASE2","title":"Combined Chemo-immunotherapy Plus SBRT in Neoadjuvant Treatment for Luminal Subtype Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-12","conditions":"HR+/HER2- Breast Cancer","enrollment":302},{"nctId":"NCT01358877","phase":"PHASE3","title":"A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-11-08","conditions":"Breast Cancer","enrollment":4804},{"nctId":"NCT04193059","phase":"PHASE3","title":"Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2019-12-20","conditions":"Breast Cancer","enrollment":1560},{"nctId":"NCT04214626","phase":"PHASE2","title":"R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Henan Cancer Hospital","startDate":"2020-01-05","conditions":"Diffuse Large B Cell Lymphoma","enrollment":60},{"nctId":"NCT01710176","phase":"PHASE3","title":"Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy","status":"COMPLETED","sponsor":"Italian Sarcoma Group","startDate":"2011-06-01","conditions":"Localized High-risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults","enrollment":550},{"nctId":"NCT07016399","phase":"PHASE2","title":"Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC","status":"RECRUITING","sponsor":"Vandana Abramson","startDate":"2025-09-09","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma","enrollment":51},{"nctId":"NCT03036488","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-03-07","conditions":"Triple Negative Breast Neoplasms","enrollment":1174},{"nctId":"NCT00462696","phase":"NA","title":"MRI in Evaluating Early Response to Chemotherapy in Women With Infiltrating Breast Cancer","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2006-02","conditions":"Breast Cancer","enrollment":16},{"nctId":"NCT04877821","phase":"PHASE2","title":"The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2021-09-15","conditions":"Triple Negative Breast Cancer","enrollment":31},{"nctId":"NCT00872625","phase":"PHASE1","title":"Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"Centre Antoine Lacassagne","startDate":"2007-04","conditions":"Breast Cancer","enrollment":26},{"nctId":"NCT07197697","phase":"PHASE2","title":"A Phase II Exploratory Study of Iparomlimab and Tuvonralimab Combined With Chemotherapy in Neoadjuvant Treatment of HR+/HER2- Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2025-10-10","conditions":"Breast Cancer","enrollment":30},{"nctId":"NCT06470464","phase":"PHASE2","title":"Thalidomide Combined With Chemotherapy in the Treatment of Relapsed or Refractory Yolk Sac Tumor","status":"COMPLETED","sponsor":"Shandong First Medical University","startDate":"2021-11-11","conditions":"Germ Cell Tumor, Yolk Sac Tumor","enrollment":20},{"nctId":"NCT07178093","phase":"NA","title":"Effects of Antrodia Cinnamomea on the Hepatoma Patients After Transcatheter Hepatic Artery Chemoembolization","status":"RECRUITING","sponsor":"Taichung Tzu Chi Hospital","startDate":"2023-01-01","conditions":"Hepatocellular Carcinoma, Transarterial Chemoembolization","enrollment":60},{"nctId":"NCT04335669","phase":"PHASE3","title":"NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lund University Hospital","startDate":"2019-12-20","conditions":"Breast Cancer, Triple Negative Breast Neoplasms","enrollment":325},{"nctId":"NCT03515798","phase":"PHASE2","title":"Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Paoli-Calmettes","startDate":"2018-08-29","conditions":"Inflammatory Breast Cancer","enrollment":52},{"nctId":"NCT04138719","phase":"PHASE2","title":"Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2019-11-20","conditions":"Breast Cancer, Triple-negative Breast Cancer, Nab-paclitaxel","enrollment":520},{"nctId":"NCT05900206","phase":"PHASE2","title":"Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2023-10-26","conditions":"Breast Cancer","enrollment":370},{"nctId":"NCT05582499","phase":"PHASE2","title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-01","conditions":"Breast Neoplasm, Breast Cancer, Breast Tumors","enrollment":716},{"nctId":"NCT02363400","phase":"PHASE3","title":"A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA","status":"TERMINATED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2014-12-14","conditions":"Nasopharyngeal Carcinoma","enrollment":10},{"nctId":"NCT06323382","phase":"","title":"Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-01-01","conditions":"Advanced Hepatocellular Carcinoma, Anti-PD1/PDL1 Antibody, Bevacizumab","enrollment":240},{"nctId":"NCT06874933","phase":"PHASE2","title":"Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-05-04","conditions":"HR+/HER2- Breast Cancer","enrollment":35},{"nctId":"NCT06611813","phase":"PHASE2","title":"Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-06-11","conditions":"HR+/HER2- Breast Cancer","enrollment":30},{"nctId":"NCT00005584","phase":"PHASE3","title":"Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1998-10","conditions":"Lymphoma","enrollment":1649},{"nctId":"NCT06358573","phase":"PHASE2","title":"Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK","status":"RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2024-10-24","conditions":"Triple-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer","enrollment":54},{"nctId":"NCT05862064","phase":"PHASE3","title":"A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-06-01","conditions":"TNBC - Triple-Negative Breast Cancer","enrollment":606},{"nctId":"NCT06914440","phase":"PHASE2","title":"Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2025-06-05","conditions":"Breast Cancer","enrollment":27},{"nctId":"NCT03725059","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-27","conditions":"Breast Cancer","enrollment":1240},{"nctId":"NCT02455141","phase":"PHASE3","title":"Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2016-03","conditions":"Breast Neoplasm","enrollment":786},{"nctId":"NCT06500208","phase":"PHASE2","title":"Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-11-01","conditions":"Breast Cancer","enrollment":48},{"nctId":"NCT06394661","phase":"PHASE2","title":"Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-04-28","conditions":"Breast Cancer","enrollment":109},{"nctId":"NCT06860529","phase":"PHASE2","title":"Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2025-04-15","conditions":"HR+/HER2- Breast Cancer","enrollment":357},{"nctId":"NCT06781281","phase":"","title":"NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-12-04","conditions":"Breast Cancer Invasive","enrollment":709},{"nctId":"NCT01630083","phase":"PHASE2","title":"Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2012-07-19","conditions":"CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Adenocarcinoma of Esophagus, CLDN18.2-positive Gastric Adenocarcinoma","enrollment":252},{"nctId":"NCT01354522","phase":"PHASE3","title":"TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2011-05","conditions":"Breast Cancer","enrollment":204},{"nctId":"NCT07016126","phase":"PHASE3","title":"D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2024-12-22","conditions":"NSCLC (Non-small Cell Lung Cancer)","enrollment":70},{"nctId":"NCT03314805","phase":"PHASE2","title":"PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy","status":"COMPLETED","sponsor":"PhytoHealth Corporation","startDate":"2018-03-01","conditions":"Cancer-related Fatigue, Neutropenia, Malignant","enrollment":67},{"nctId":"NCT06955702","phase":"NA","title":"Effect of Cryotherapy in the Prevention of Madarosis Produced by Chemotherapy in Breast Cancer Patients","status":"RECRUITING","sponsor":"University of Salamanca","startDate":"2023-11-15","conditions":"Breast Neoplasms, Alopecia, Madarosis","enrollment":120},{"nctId":"NCT06975644","phase":"NA","title":"Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2025-09-01","conditions":"Triple-Negative Breast Cancer (TNBC), Neoadjuvant Chemotherapy, Chemotherapy Effects","enrollment":55},{"nctId":"NCT06977893","phase":"PHASE3","title":"Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-03-24","conditions":"HR+/HER2- Breast Cancer","enrollment":194},{"nctId":"NCT06977542","phase":"PHASE2","title":"Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-06","conditions":"TNBC, Triple Negative Breast Cancer","enrollment":53},{"nctId":"NCT03201861","phase":"PHASE3","title":"Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2017-07-27","conditions":"Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Duct Carcinoma of Breast","enrollment":762},{"nctId":"NCT06964906","phase":"PHASE2","title":"Study of High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab Plus Chemotherapy Versus Chemotherapy as Neoadjuvant Therapy for Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (NeoHunter)","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-03-04","conditions":"ER+/HER2- Breast Cancer","enrollment":140},{"nctId":"NCT06961500","phase":"PHASE2","title":"Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-05-01","conditions":"Follicular Lymphoma Grade 3A","enrollment":133},{"nctId":"NCT04668365","phase":"PHASE2","title":"Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"SUSPENDED","sponsor":"Henan Cancer Hospital","startDate":"2020-12-25","conditions":"Diffuse Large B Cell Lymphoma, CD79A Gene Mutation, CD79B Gene Mutation","enrollment":59},{"nctId":"NCT06941038","phase":"","title":"Intraoperative vs. Postoperative Intravesical Epirubicin Instillation for Prevention of Bladder Recurrence in High-Risk Upper Urinary Tract Urothelial Carcinoma","status":"COMPLETED","sponsor":"Ankara Etlik City Hospital","startDate":"2021-06-01","conditions":"Bladder Cancer Recurrence, Intravesical Instillation, Upper Urinary Tract Carcinoma","enrollment":270},{"nctId":"NCT06140966","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2023-10-20","conditions":"Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma","enrollment":54},{"nctId":"NCT01779206","phase":"PHASE2, PHASE3","title":"ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer","status":"COMPLETED","sponsor":"West German Study Group","startDate":"2012-05","conditions":"Breast Cancer","enrollment":4936},{"nctId":"NCT06844357","phase":"PHASE2, PHASE3","title":"A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.","status":"RECRUITING","sponsor":"Zhejiang Raygene Pharmaceuticals Co., Ltd","startDate":"2025-03-27","conditions":"HCC","enrollment":300},{"nctId":"NCT06908668","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-03-31","conditions":"HER2-Negative Locally Advanced Breast Cancer","enrollment":170},{"nctId":"NCT06766266","phase":"PHASE1","title":"Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment","status":"RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2025-01-10","conditions":"Non-Muscle Invasive Bladder Urothelial Carcinoma","enrollment":18},{"nctId":"NCT04296175","phase":"PHASE3","title":"Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2020-03-05","conditions":"Triple-negative Breast Cancer","enrollment":808},{"nctId":"NCT06890585","phase":"PHASE2","title":"Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Li Zhiming","startDate":"2025-06-01","conditions":"BTK Inhibitors, Histone Deacetylase Inhibitor, Double Express Diffuse Large B-cell Lymphoma","enrollment":128}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":460,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_2","status":"active","brandName":"Epidoxorubicin","genericName":"Epidoxorubicin","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Epidoxorubicin is a small molecule used in chemotherapy, specifically for treating breast cancer, including ER+/HER2- breast cancer. It is often used in combination with other medications, such as chemotherapy, for the treatment of breast cancer in patients who have undergone surgery.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}